Swiss cancer vaccine biotech Nouscom raises $72M Series C for PhII trials

Kyle LaHucik

Senior Reporter

Basel-based biotech Nouscom has raised €67.5 million ($72.2 million) to bankroll its cancer vaccines as the eight-year-old company looks to capitalize on momentum in the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Swiss cancer vaccine biotech Nouscom raises $72M Series C for PhII trials

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Swiss can­cer vac­cine biotech Nous­com rais­es $72M Se­ries C for PhII tri­als

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Swiss cancer vaccine biotech Nouscom raises $72M Series C for PhII trials